Fulviglen 250 mg/5 mL Fulviglen 250 mg/5 mL contains Fulvestrant, a hormonal therapy used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It helps control the growth of cancer by reducing the activity of estrogen, a hormone that can stimulate certain breast cancer cells. By lowering the effect of estrogen on these cells, Fulviglen helps slow disease progression and supports long-term cancer management. It is administered as an intramuscular injection under the supervision of a qualified healthcare professional.